In vitro and in vivo studies have demonstrated that co-occurring mutations of STK11 and KEAP1 in KRAS-mutant NSCLC promote tumor growth and confer enhanced resistance to radiotherapy (116). The gene discussed is STK11; the disease is neoplasm.